Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.4.24.35: gelatinase B

This is an abbreviated version!
For detailed information about gelatinase B, go to the full flat file.

Word Map on EC 3.4.24.35

Reaction

Cleavage of gelatin types I and V and collagen types IV and V =

Synonyms

92 kDa gelatinase, 92 kDa type IV collagenase, 92 kDa type IV collagenase proMMP-9, 92-kDa Gelatinase, 92-kDa gelatinase B, 92-kDa Type IV collagenase, 95 kDa type IV collagenase/gelatinase, Collagenase IV, Collagenase type IV, gelatinase, gelatinase B, Gelatinase MMP 9, gelatinolytic enzyme, GELB, Macrophage gelatinase, matrix metallopeptidase 9, matrix metallopeptidase 9 gelatinase B, matrix metalloprotease-9, Matrix metalloproteinase 9, matrix metalloproteinase-9, metrix metalloproteinase-9, MMP 9, MMP-9, MMP9, neutrophil collagenase, pro-matrix metalloproteinase-9, progelatinase, Type IV collagen metalloproteinase, Type IV collagenase, Type IV collagenase/gelatinase, Type V collagenase

ECTree

     3 Hydrolases
         3.4 Acting on peptide bonds (peptidases)
             3.4.24 Metalloendopeptidases
                3.4.24.35 gelatinase B

Inhibitors

Inhibitors on EC 3.4.24.35 - gelatinase B

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2E)-3-(N-hydroxycarbamoyl)-2-(3-phenylpropylidene)propionyl-L-tryptophan-N-methylamide
-
-
(2E)-3-(N-hydroxycarbamoyl)-2-heptylidenepropionyl-L-tryptophan-N-methylamide
-
-
(2E)-3-(N-hydroxycarbamoyl)-2-isopropionyl-L-tryptophan-N-methylamide
-
-
(2E)-3-(N-hydroxycarbamoyl)-2-[(2E)-3-phenylprop-2-en-1-ylidene]propionyl-L-tryptophan-N-methylamide
-
-
(2E)-3-(N-hydroxycarbamoyl)-2-[(2E)-but-2-en-1-ylidene]propionyl-L-tryptophan-N-methylamide
-
-
(R)-2-(N-((6-fluoropyridin-3-yl)methyl)-4-methoxyphenyl-sulfonamido)-N-hydroxy-3-methylbutanamide
-
-
(S)-2,4-bis[(2,3-dihydroxybenzoyl)amino]butyric acid methyl ester
-
-
(S)-2,5-bis[(2,3-dihydroxybenzoyl)amino]pentanoic acid methyl ester
-
-
(S)-2,6-bis[(2,3-dihydroxybenzoyl)amino]-N-hydroxyhexanoamide
-
-
(S)-2,6-bis[(2,3-dihydroxybenzoyl)amino]hexanenitrile
-
-
(S)-2,6-bis[(2,3-dihydroxybenzoyl)amino]hexanoamide
-
shows 33% inhibition against MMP-9 at 0.00025 mM
(S)-2,6-bis[(2,3-dihydroxybenzoyl)amino]hexanoic acid
-
-
(S)-2,6-bis[(2,3-dihydroxybenzoyl)amino]hexanoic acid methyl ester
-
-
(S)-2,6-bis[(2,3-dimethoxybenzoyl)amino]hexanoic acid methyl ester
-
-
(S)-2,7-bis[(2,3-dihydroxybenzoyl)amino]heptanoic acid methyl ester
-
-
(S)-2-acetyl-6-[(2,3-dihydroxybenzoyl)amino]hexanoic acid methyl ester
-
-
(S)-2-benzoylamino-6-[(2,3-dihydroxybenzoyl)amino]-hexanoamide
-
-
(S)-2-benzoylamino-6-[(2,3-dihydroxybenzoyl)amino]-hexanoic acid methyl ester
-
-
(S)-6-benzoylamino-2-[(2,3-dihydroxybenzoyl)amino]-hexanoic acid methyl ester
-
-
1,10-phenanthroline
1,5-bis[(2,3-dihydroxybenzoyl)amino]pentane
-
-
2-[(biphenyl-4-ylsulfonyl)(isobutyl)amino]-N-hydroxyacetamide
-
50% inhibition at 34 nM, comparison with inhibitory effect on matrix metalloproteinases MMP-3, MMp-7, MMP-2
3',4',5,6,7,8-hexamethoxyflavone
-
i.e. nobiletin
3',4'-di-O-methylbutin-7-O-[(6''->1''')-3''',11'''-dimethyl-7'''-methylenedodeca-3''',10'''-dienyl]-beta-D-glucopyranoside
-
0.0065-0.0259 mM suppresses MMP-9 activity in lipopolysaccharide-stimulated human monocytic cells without cytotoxicity
3',4'-di-O-methylquercetin-7-O-[(4''->13''')-2''',6''',10''',14'''-tetramethylhexadec-13'''-ol-14'''-enyl]-beta-D-glucopyranoside
-
0.0065-0.0259 mM suppresses MMP-9 activity in lipopolysaccharide-stimulated human monocytic cells without cytotoxicity
3',4'-dihydroxy-5,6,7,8-tetramethoxyflavone
-
-
3'-hydroxy-4',5,6,7,8-pentamethoxyflavone
-
-
4'-hydroxy-3',5,6,7,8-pentamethoxyflavone
-
-
4'-O-methylbutin-7-O-[(6->1''')-3''',11'''-dimethyl-7'''-hydroxymethylenedodecanyl]-beta-D-glucopyranoside
-
0.0065-0.0259 mM suppresses MMP-9 activity in lipopolysaccharide-stimulated human monocytic cells without cytotoxicity
4'-O-methylkaempferol-3-O-[(4''->13''')-2''',6''',10''',14'''-tetramethylhexadecan-13'''-olyl]-beta-D-glucopyranoside
-
0.0065-0.0259 mM suppresses MMP-9 activity in lipopolysaccharide-stimulated human monocytic cells without cytotoxicity
5-(1,5-dihydroxypentan-3-yl)-5-(4-phenoxyphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-(4-hydroxybutan-2-yl)-5-(4-phenoxyphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-(4-phenoxyphenyl)-5-(3-(1-nitrooxy-methyl)piperidin-1-yl)-pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-(4-phenoxyphenyl)-5-(4-(1-nitrooxy-ethyl)piperidin-1-yl)-pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-(4-phenoxyphenyl)-5-(4-(2-nitrooxy-ethyl)piperazin-1-yl)-pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-(4-phenoxyphenyl)-5-(4-(2-nitrooxy-ethyl)piperidin-1-yl)-pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-(4-phenoxyphenyl)-5-(bis-(2-nitrooxy-ethyl)-amino)pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-(4-phenoxyphenyl)-5-(methyl-(2-nitrooxy-ethyl)-amino)-pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-[3-(hydroxymethyl)piperidin-1-yl]-5-(4-phenoxyphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-[4-(2-hydroxyethyl)piperazin-1-yl]-5-(4-phenoxyphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-(4-phenoxyphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-[4-(hydroxymethyl)piperidin-1-yl]-5-(4-phenoxyphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
adiponectin
-
adiponectin can markedly suppress protein expression and activity of MMP9 in brain, induced by 1 h ischemia followed by 23 h reperfusion
-
Ag-3340
-
i.e. N-hydroxy-2,2-dimethyl-4-[(4-phenoxyphenyl)sulfonyl]thiomorpholine-3-carboxamide, 50% inhibition at 0.26 nM, comparison with inhibitory effect on matrix metalloproteinases MMP-3, MMp-7, MMP-2
alpha-linolenic acid
-
antibody REGA-3G12
highly selective, potent MMP-9 inhibition, the antibody recognizes the N-terminal part, not the C-terminal hemopexin and O-glycosylated domains, epitope mapping, overview
-
AZD-6140
-
-
BB-94
BB1101
-
MMP inhibitor
BIIL284
-
BIIL284 treatment (3 mg/kg once daily for 2 weeks) significantly reduces the extracellular matrix metalloproteinase-9 activity in stented arteries
carboxy-derivatized glucosamine
-
62% inhibition of MMP-9 at 0.5 mg/ml
-
CGS 27023A
-
-
CGS27023A
-
50% inhibition at 8 nM, comparison with inhibitory effect on matrix metalloproteinases MMP-3, MMp-7, MMP-2
chitooligosaccharides
-
different molecular weight, inhibit both MMP-9 expression and activity, especially 1- to 3-kDa chitooligosaccharides, chitooligosaccharides-I in HT-1080 cells
cyclic CTT peptide
-
a gelatinase inhibitor peptide
cyclic CTTHWGFTLC
-
a specific gelatinase inhibitor
D-penicillamine
-
10 mg/l, 43% inhibition
docosahexaenoic acid
-
doxycyclin
-
doxycycline significantly inhibits MMP-9 activity in gel zymography and also suppressed in situ gelatinase activity
doxycycline
gamma-linolenic acid
-
GM6001
hemopexin domain of MMP-9
the hemopexin domain of MMP-9 inhibits the degradation of gelatin. It also abolishes the degradation of gelatin by MMP-2. Blades 1 and 4 of the PEX9 domain are responsible for the gelatin degradation inhibitory activity of PEX9. The hemopexin domain of MMP-9 does not prevent the degradation of other MMP-9 substrates, such as a fluorogenic peptide, alphaB crystalline, or nonmuscular actin
-
ilomastat
Immunoglobulins purified from antisera raised against gelatinase
-
-
-
isovitexin
interacts with enzyme residues Glu241, Ala242, Pro255, Pro254, Thr251, Leu222, Tyr248, Arg241, Met247, His226, and Glu227, binding structure analysis, and modeling, overview
linoleic acid
-
macroglobulin
-
-
-
marimastat
-
-
Melatonin
-
i.e. N-acetyl-5-methoxytryptamine, used in protection during gastric ulcer, arresting cell injury, protein carbonyl formation, and lipid peroxidation in mice during gastroprotection, inhibits MMP-9 expression and activity
minocycline
-
0.02 mM minocycline displays inhibitory action on MMP-9 expression and activity
MMP-9 inhibitor I
MMP-9i
-
MMP-9 inhibitor, an anthranilate hydroxamic acid derivative
-
MMP9 inhibitor I
-
-
N,N'-[(2S)-6-[[(2,3-dihydroxyphenyl)carbonyl]amino]hexane-1,2-diyl]bis(2,3-dihydroxybenzamide)
-
-
N-hydroxy-2-(isobutyl[(4-methoxyphenyl)sulfonyl]amino)acetamide
-
50% inhibition at 2.9 nM, comparison with inhibitory effect on matrix metalloproteinases MMP-3, MMp-7, MMP-2
N-isobutyl-N-(4-methoxyphenylsulfonyl)glycyl hydroxamic acid
NNGH
N-[(5R)-5-[[(2,3-dihydroxyphenyl)carbonyl]amino]-6-hydroxyhexyl]-2,3-dihydroxybenzamide
-
-
N-[(5S)-5-[[(2,3-dihydroxyphenyl)carbonyl]amino]-6-hydroxyhexyl]-2,3-dihydroxybenzamide
-
-
N-[(5S)-6-amino-5-[[(2,3-dihydroxyphenyl)carbonyl]amino]hexyl]-2,3-dihydroxybenzamide
-
-
norcantharidin
-
i.e. exo-7-oxabicylo-[2.2.1] heptane-2,3-dicarboxylic anhydride, norcantharidin inhibits gelatinase activity of MM-9 in a concentration- and time-dependent manner
o-phenanthroline
-
-
oleic acid
-
Phenanthroline
-
-
pioglitazone
-
pioglitazone reduces the upregulation of active form of MMP-9 after ischemia
polyhistidine
-
0.001 mM, 68% inhibition
proanthocyanidins
-
from the american cranberry, Vaccinium macrocarpon, decrease cellular viability of DU-145 cells via inhibition of MMP-9. The proanthocyanidins PACs increase the expression of TIMP-2, a known inhibitor of MMP activity, and decrease the expression of EMMPRIN, an inducer of MMP expression. Cranberry proanthocyanidins decrease MMP activity through the induction and/or inhibition of specific temporal MMP regulators, and by affecting either the phosphorylation status and/or expression of MAP kinase, PI-3 kinase, NF-kappaB and AP-1 pathway proteins
-
procyanidin oligomers
-
from Japanese quince, Chaenomeles japonica, fruit inhibit activity of MMP-9
-
REGA-3G12 scFv with (His6)2
-
monoclonal antibody REGA-3G12 single-chain variable fragment, 0.005 mM, 66% inhibition
-
reversion-inducing cysteine-rich protein with Kazal motifs
-
-
SB-3CT
TIMP-1
-
TIMP-1/2
-
-
-
TIMP-2
-
TIMP-4
-
-
-
TIMP1
-
interaction analysis and structure modeling, overview
-
TIMP2
-
interaction analysis and structure modeling, overview
-
Tissue inhibitor
-
tissue inhibitor of matrix metalloproteinase 1
-
strong inhibitor of MMP-9
-
tissue inhibitor of matrix metalloproteinase-1
-
TIMP-1
-
tissue inhibitor of metalloproteinase 1
-
-
-
tissue inhibitor of metalloproteinase TIMP-1
-
-
tissue inhibitor of metalloproteinase TIMP-2
-
-
Tissue inhibitor of metalloproteinase-1
-
Tissue inhibitor of metalloproteinase-2
-
-
tissue inhibitor of metalloproteinases 1
-
tissue inhibitor of metalloproteinases 2
-
TIMP-2, complete inhibition at 0.5 mg
-
tissue inhibitor of metalloproteinases-1
-
i.e. TIMP-1, plays a crucial role in the pathogenesis of hepatic fibrosis and thus may represent an important therapeutic target in the design of anti-fibrotic strategiesfor chronic liver disease, overview, molecular modeling of the three-dimensional structure of the MMP-9/TIMP-1 complex, overview
-
vitexin
interacts with enzyme residues Gly186, Pro246, His236, Met247, Tyr248, Val223, and Leu188, binding structure analysis, and modeling, overview
additional information
-